NASDAQ: PTGXProtagonist Therapeutics Inc Stock
$98.03+0.65 (+0.67%)
Updated Jun 8, 2026
PTGX Price
$98.03
Fair Value Price
-$4.03
Market Cap
$6.30B
52 Week Low
$49.38
52 Week High
$107.84
P/E
-54.16x
P/B
9.62x
P/S
92.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.06M
Earnings
-$114.71M
Gross Margin
100%
Operating Margin
-155.78%
Profit Margin
-154.9%
Debt to Equity
0.06
Operating Cash Flow
-$117M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTGX Overview
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTGX's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTGX
Ranked#9 of 462
Ranked#9 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $232.04 | A | |
| $51.74 | A | |
| $15.66 | A |
Be the first to know about important PTGX news, forecast changes, insider trades & much more!
PTGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTGX ($98.03) is overvalued by 2,535.34% relative to our estimate of its Fair Value price of -$4.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PTGX ($98.03) is not significantly undervalued (2,535.34%) relative to our estimate of its Fair Value price of -$4.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PTGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PTGX due diligence checks available for Premium users.
Valuation
PTGX fair value
Fair Value of PTGX stock based on Discounted Cash Flow (DCF)
Price
$98.03
Fair Value
-$4.03
Undervalued by
2,535.34%
PTGX ($98.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PTGX ($98.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PTGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PTGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-54.16x
Industry
18.56x
Market
14.72x
PTGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.62x
Industry
4.68x
PTGX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTGX's financial health
Profit margin
Revenue
$56.4M
Net Income
$3.8M
Profit Margin
6.7%
PTGX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$697.5M
Liabilities
$42.0M
Debt to equity
0.06
PTGX's short-term assets ($613.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTGX's short-term assets ($613.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$48.9M
Investing
$90.9M
Financing
$23.4M
PTGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTGX vs Biotech Stocks
Protagonist Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.